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Abstract
Objective To develop a visual rating scale for posterior
atrophy (PA) assessment and to analyse whether this scale
aids in the discrimination between Alzheimer’s disease
(AD) and other dementias.
Methods Magnetic resonance imaging of 118 memory
clinic patients were analysed for PA (range 0–3), medial
temporal lobe atrophy (MTA) (range 0–4) and global
cortical atrophy (range 0–3) by different raters. Weighted-
kappas were calculated for inter- and intra-rater agreement.
Relationships between PA and MTA with the MMSE and
age were estimated with linear-regression analysis.
Results Intra-rater agreement ranged between 0.93 and 0.95
and inter-rater agreement between 0.65 and 0.84. Mean PA
scores were higher in AD compared to controls (1.6±0.9 and
0.6±0.7, p<0.01), and other dementias (0.8±0.8, p<0.01). PA
was not associated with age compared to MTA (B=1.1 (0.8)
versus B=3.1 (0.7), p<0.01)). PA and MTA were indepen-
dently negatively associated with the MMSE (B=−1.6 (0.5),
p<0.01 versus B=−1.4 (0.5), p<0.01).
Conclusion This robust and reproducible scale for PA
assessment conveys independent information in a clinical
setting and may be useful in the discrimination of AD from
other dementias.
Keywords Alzheimer . Dementia . MRI . Posterior atrophy
Introduction
Alzheimer’s disease (AD) has been considered clinically
homogenous and characterized by progressive memory impair-
ment followed by global cognitive decline [1]. The clinical
diagnosis of AD depends largely on the presenting cognitive
profile. However, atypical focal presentations of AD may be
more common than previously thought, which can make a
E. L. G. E. Koedam (*) :W. M. van der Flier : P. Scheltens :
Y. A. L. Pijnenburg
Department of Neurology and Alzheimer Centre,
VU University Medical Centre,
PO Box 7057, 1007 MB Amsterdam, The Netherlands
e-mail: elge.koedam@vumc.nl
W. M. van der Flier
e-mail: WM.vdFlier@vumc.nl
P. Scheltens
e-mail: p.scheltens@vumc.nl
Y. A. L. Pijnenburg
e-mail: Y.Pijnenburg@vumc.nl
F. Barkhof :M. P. Wattjes
Department of Radiology, VU University Medical Centre,
PO Box 7057, 1007 MB Amsterdam, the Netherlands
F. Barkhof
e-mail: f.barkhof@vumc.nl
M. P. Wattjes
e-mail: m.wattjes@vumc.nl
W. M. van der Flier
Department Epidemiology and Biostatistics,
VU University Medical Centre,
PO Box 7057, 1007 MB Amsterdam, the Netherlands
M. Lehmann :N. Fox
Dementia Research Centre, UCL Institute of Neurology,
Queen Square,
London, UK
M. Lehmann
e-mail: lehmann@drc.ion.ucl.ac.uk
N. Fox
e-mail: nfox@dementia.ion.ucl.ac.uk
Eur Radiol (2011) 21:2618–2625
DOI 10.1007/s00330-011-2205-4
clinical diagnosis difficult [1–3]. Neuroimaging, particularly
magnetic resonance (MR) imaging, has an established role in
excluding other, potentially treatable diagnoses, but also
increasingly recognized potential to support a clinical diagno-
sis of AD by identifying certain atrophy patterns [4, 5]. AD is
typically associated with medial temporal lobe atrophy (MTA)
[6–9]. The presence of MTA on MR imaging improves the
discrimination of AD from healthy controls and predicts
progression to dementia in patients with mild cognitive
impairment (MCI) [9, 10]. Visual MTA rating based on
established rating scales, has proven to be useful for a good
and reproducible assessment in clinical practice and correlates
well with volumetric assessments [11, 12]. However, MTA is
also present in other dementias, for example Frontotemporal
lobe degeneration (FTLD), vascular dementia (VaD) and
dementia with Lewy bodies (DLB) and may been seen in
normal aging [13–18]. Furthermore, younger AD patients
often show relatively less (or no) MTA at presentation [19].
Occasionally, AD patients present with a striking posterior
atrophy pattern- often referred to as posterior cortical atrophy.
Benson et al. were the first describing patients with evidence of
posterior cerebral involvement and prominent visual problems
and suggested possible underlying AD [20]. Early posterior
cerebral involvement is emerging as an important aspect of
AD, more generally with dysfunction and atrophy of the
posterior cingulate gyrus, precuneus and parietal lobes, being
perhaps a particular feature of early-onset (<65 years) AD
(EOAD) [3, 19, 21–27]. Posterior atrophy (PA) appears to be
characteristic of AD in patients with typical and atypical
clinical presentations and may assist in the clinical distinction
of AD from Frontotemporal lobar degeneration (FTLD) [28,
29]. Moreover, combined with relative sparing of the medial
temporal lobe, PA has found to be characteristic for patients
with atypical clinical presentations [3, 25, 30].
Limited data is available about the clinical relevance of PA
and no visual rating scale is currently available to measure
atrophy in the posterior regions, hampering systematic
evaluation of PA. The purpose of this study was to develop a
robust visual rating scale for PA assessment and evaluate intra-
and inter-observer agreement. The second aim was to
investigate the clinical relevance of PA, by comparing the
degree of PA in AD, controls and other dementias and
investigate the relationship with age and the mini-mental state
examination (MMSE) [31].
Materials and methods
Patient selection
This study was conducted at our memory clinic and
approved by the local institutional review board. Written
informed consent was obtained from all participants.
We selected 120 patients from our memory clinic popula-
tion based on their clinical diagnosis. The selection included
60 AD patients (35 EOAD (onset <65 years) and 25 late-onset
AD), 20 age-matched patients with other dementias (10 FTLD
and 10 DLB patients) and 40 age-matched patients with
subjectivememory complaints, without cognitive impairment.
The group of other dementias did not include patients with
vascular dementia, characterized by severe vascular abnor-
malities on MR imaging, since this could be of influence on
PA measurement. The diagnostic procedure consisted of a
standard battery of investigations including a patient and
informant-based medical history, physical and neurological
examination including the MMSE and multisequence MR
imaging. The clinical diagnosis of probable AD, FTLD or
DLB was made according to current criteria by a multidisci-
plinary team, including a neurologist, psychiatrist, neurophys-
iologist, neuropsychologist and specialized nurse [32–34].
The patients’ diagnosis was established on clinical criteria
and not on basis of their imaging findings. Imaging findings
did not change a patient’s diagnosis in our study group.
MR imaging
MR imaging was performed using 3.0 T MR (Signa HDxt,
General Electric, Milwaukee). Mean time between MR
imaging and diagnosis was 0.2 ±1 months. All subjects
were examined according to a standard dementia MRI
protocol: sagittal T1-weighted 3D fast spoiled gradient echo
(FSPGR) sequences (field of view (FOV) = 250 mm;
matrix = 256×256; 1 mm slices; echo time = 3 ms;
repetition time = 7.8 ms; inversion time = 450 ms; one
signal acquired), 3D fluid-attenuated inversion recovery
(FLAIR) (FOV = 250 mm; matrix = 224×224; 1 mm
slices; echo time = 125 ms; repetition time = 8,000 ms;
inversion time = 2,349 ms; echo train length 230, one
signal acquired) and axial fast spin-echo T2/PD sequences
(FOV = 250 mm; matrix = 384×384; 3 mm slices; echo
time = 20/109 ms; repetition time = 8,240 ms; echo train
length 24, two signals acquired). Multiplanar (MPR)
reconstructions of 3D-T1-weighted sequences were per-
formed in sagittal (5 mm) and oblique-coronal orientations
(3 mm slices perpendicular to the long axis of the
hippocampus), using a 5 mm section thickness. MPR
reconstructions of 3D-FLAIR images were performed in
transverse orientation using a 3 mm section thickness.
Posterior rating scale development
To define the areas included in the scale, we evaluated 25
MR examinations from probable AD patients with a wide
range of atrophy and determined the most affected posterior
regions. Secondly, we assessed these areas in 10 controls, to
determine whether these areas were more affected in AD
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patients and therefore able to represent PA. Finally, taking
into account those regions mentioned in literature, the
following anatomical regions were selected: the posterior
cingulate sulcus, precuneus, parieto-occipital sulcus and the
cortex of the parietal lobes. The MR examinations used to
determine which posterior regions to rate were not further
used in this study, to avoid any circularity.
To assess PA we designed a 4-point rating scale (0 = no
atrophy; 1 = mild widening of the sulci without evident
volume loss of the gyri; 2 = substantial widening of the
sulci and volume loss of the gyri; grade 3 = severe end-
stage atrophy). The overall score based on the presence of
atrophy in sagittal, axial and coronal orientation, was
assessed for left and right separately on sagittal and coronal
MPR sections of the T1-weighted sequence and axial MPR
sections of the FLAIR sequence.
Characteristics of the posterior rating scale
The following anatomical landmarks were rated in three
different orientations:
a) sagittal orientation: widening of the posterior cingulate-
and parieto-occipital sulcus, and atrophy of the pre-
cuneus on left and right by considering paramedian-
sagittal images.
b) axial orientation: widening of the posterior cingulate
sulcus and sulcal dilatation in parietal lobes on axial
images.
c) coronal orientation: widening of the posterior cingulate
sulcus and parietal lobes on coronal images.
Grade 0 represents a closed posterior cingulate- and
parieto-occipital sulcus and closed sulci of the parietal lobes
and precuneus. Grade 1 includes a mild widening of the
posterior cingulate- and parieto-occipital sulcus, with mild
atrophy of the parietal lobes and precuneus. Grade 2 shows
substantial widening of the posterior cingulate- and parieto-
occipital sulcus, with substantial atrophy of the parietal lobes
and precuneus. Grade 3 represents end-stage atrophy with
evident widening of both sulci and knife-blade atrophy of the
parietal lobes and precuneus (the different grades of atrophy
are shown in Figure 1). In case of different scores on different
orientations (e.g. score 1 on sagittal direction and score 2 on
axial direction), the highest score was considered.
Image analysis
All 120 MR examinations were rated for PA by three
different raters (rater 1: neuroradiologist, 8-year experience
in imaging in dementia, rater 2: MD working as PhD-
student and rater 3: PhD-student, both 3-year experience in
imaging in dementia). All raters were blinded for the
clinical diagnosis and paraclinical tests. Twenty-nine MR
examinations were rated twice by two observers (rater 1
and 2) to assess intra-rater agreement. All MR examinations
were rated for MTA using a 5-point rating scale (0–4) and
for global cortical atrophy (GCA) by two raters (rater 1 and
2) using a 4-point (0–3) rating scale.[9, 35] GCA was
assessed on axial MPR sections of the FLAIR sequence and
MTAwas assessed on oblique-coronal MPR sections of the
T1-weighted sequence.
Statistical analysis
For statistical analysis we used averaged scores of the left
and right hemisphere for the posterior scale and MTA scale.
Basic demographic data were examined using Chi-square
tests for categorical data and t-tests for continuous data. To
analyse differences in mean atrophy scores between the
groups, scores of one rater (rater 1) were used. To quantify
inter- and intra-observer agreement we calculated weighted-
kappa’s between each pair of observers and between the
first and second session of two raters separately. For
weighted-kappa values, degree of agreement was defined
according to Landis and Koch [36].
Linear-regression analysis was used to analyse relation-
ships between scores on each visual rating scale and age and
MMSE score. In the first model relationships of each visual
rating scale (independent variable) with either MMSE or age
(dependent variable) were assessed unadjusted. In the second
model the same relationships were assessed, corrected for age
and sex in the analysis with the MMSE and corrected for sex
in the analysis with age. In the third model both visual rating
scales were entered simultaneously, together with the same
covariates. Results are presented as linear-regression coef-
ficients with standard error, B (SE). Statistical significance
was set at p<0.05.
Results
Patient characteristics
Two controls were excluded, since sagittal T1-weighted
sequences were missing, resulting in a total group of 118
patients (60 AD, 20 other dementias and 38 controls).
Table 1 shows demographical and imaging characteristics
of the study population. The groups were similar with
respect to age. Sex was equally distributed within AD
patients and controls (roughly 50% female), whereas women
made up 25% of other dementias patients (p<0.05). Disease
duration (time between first symptoms and diagnosis) did
not differ between AD and other dementias. Mean MTA
scores were higher in AD compared with controls (1.3±1.0
versus 0.4±0.7, p<0.01), but did not differ from other
dementias (1.2±1.0). GCA scores were higher in AD
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compared with controls (1.1±0.7 versus 0.2±0.5, p<0.01)
and other dementias (0.7±0.7, p<0.05).
Mean scores on the PA rating scale were higher in AD
compared with controls (1.6±0.9 and 0.6±0.7, p<0.01) and
other dementias (0.8±0.8, p<0.01). PA scores did not differ
between other dementias and controls.
Rater agreement
Intra-rater agreement (determined in 29 MR examinations
for 2 raters) for PA was excellent with a weighted-kappa
value of 0.93 (rater 1) and 0.95 (rater 2). Inter-rater
agreement (determined in 118 examinations for 3 rater
Fig.1 Visual rating scale for the posterior brain regions. In sagittal, axial
and coronal orientation, this rating scale rates 0 = no atrophy, 1 = minimal
atrophy, 2 = moderate atrophy and 3 = severe atrophy. In sagittal
orientation, widening of posterior cingulate- and parieto-occipital sulcus
and atrophy of the precuneus was evaluated. In axial orientation, the
widening of the posterior cingulate sulcus and sulcal dilatation in the
parietal lobes was evaluated. In coronal orientation, the widening of the
posterior cingulate sulcus and sulcal dilatation in the parietal lobes was
evaluated (reproduced from "Neuroimaging in Dementia" by Barkhof et
al., 2011, fig.3.10 © Springer Science + Business Media). Abbreviations:
PSC posterior cingulate sulcus, POS parieto-occipital sulcus, PRE
precuneus and PAR parietal lobe
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pairings) was best between rater 1 and 2, with a value of
0.84, followed by a value of 0.70 between rater 2 and 3 and
lowest between rater 1 and 3, with a value of 0.65. The
average value for inter-rater agreement (0.73) was good.
Intra-rater agreement for MTA varied between 0.91 and
0.95, whereas values for inter-rater agreement varied
between 0.82 (rater 1 and 3) and 0.90 (rater 1 and 2 and
rater 2 and 3) (Table 2). GCA was only rated by two raters
(rater 1 and 2), intra-rater agreement was 0.85 for both raters
and inter-rater agreement was 0.70.
Clinical correlations
In a separate analysis we investigated relationships between
PA and MTA with either age or MMSE across the entire
group (Table 3). Higher ratings of MTA were associated
with older age (B=3.1 (0.7), p<0.01) and lower MMSE
scores (B=−2.0 (0.5), p<0.01). By contrast, PA was not
related to age, but there was an equally strong relationship
with MMSE scores (B=−1.8 (0.5), p<0.01)). These results
remained essentially unchanged when both scales were
entered into the same model, illustrating their independent
effects on cognitive deterioration.
Rating scales: sensitivity and specificity
To further investigate how MTA and PA contribute to AD,
we investigated the degree of MTA and PA in AD, controls
and other dementias (Table 4). We therefore dichotomized
scores for MTA and PA, with an average score of >1 being
considered abnormal for both rating scales. Most of the
controls had normal scores (≤1) for MTA and PA (N=33,
88%). A minority had either MTA or PA, but none of the
controls had abnormal scores (>1) for both regions. In AD,
28% had prominent PA (scores >1) without evident MTA,
whereas only 15% had prominent MTA (scores >1) without
evident PA. Minimal MTA and PAwas found in 27% of the
AD patients. The sensitivity of PA for AD was 58%, with a
specificity of 95%, whereas MTA had a sensitivity of 45%
with a specificity of 92%. Combining MTA and PA
(combining patients with either MTA or PA, or a combina-
tion of both) increased sensitivity to 73% and slightly
decreased specificity to 87%.
Most other dementia patients had normal scores for MTA
and PA (N=9, 45%).
When we looked at early- and late-onset AD separately,
it became obvious that in late-onset AD approximately the
same proportion had either prominent PA or MTA (20%
versus 16%). However, in EOAD, 34% had prominent PA,
whereas only 14% had prominent MTA. Disease duration
did not differ between early- and late-onset AD (3.3 years±
1.9 versus 3.0 years±1.6, p=0.5).
Discussion
PA is seen in a substantial proportion of AD patients,
perhaps particularly in those with an early onset. Because
of the complexity of anatomy and variability in posterior
regions, this atrophy may be less obvious to inspection than
MTA. Moreover, a visual rating scale for PA has been
lacking. With this study we aimed to develop a robust
visual rating scale, to detect the wide range and complexity
of PA. We found that agreement on visual assessment of PA
Table 1 demographic characteristics and imaging measurements per patient group
Controls AD Other dementias
N 38 60 20
Females 20 (53%)~ 30 (50%)~ 5 (25%)
Age (at diagnosis) 65.4 y (7) 66.4 y (10) 62.0 y (5)
Duration of symptoms – 3.2 y (2) 4.7 y (5)
MMSEa 29 (20–30)/28 (2) 21 (9–30)/20 (4)* ~ 24 (17–30)/25 (4)*
MTA 0 (0–3)/0.4 (0.7) 1 (0–4)/1.3 (1.0)* 1 (0–4)/1.2 (1.0)*
GCA 0 (0–2)/0.2 (0.5) 1 (0–2)/1.1 (0.7)* ~ 1 (0–2)/0.7 (0.7)#
PA 0 (0–3)/0.6 (0.7) 0 (0–3)/1.6 (0.9)*† 0 (0–2)/0.8 (0.8)
Data are presented as median (range)/mean (SD) or N (%)
* p<0. 01 compared to controls
# p<0. 05 compared to controls
† p<0.01 compared to other dementias
~ p<0. 05 compared to other dementias
aMMSE available for 114 patients
AD Alzheimer’s disease, N number of patients, MMSE mini-mental state examination, MTA medial temporal lobe atrophy, GCA global cortical
atrophy, y years and PA posterior atrophy
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varied between good and excellent. Furthermore, higher PA
scores were found in AD compared to controls and other
dementias and therefore the scale may be useful in the
discrimination between AD and other dementias.
Several studies have shown that the precuneus, parietal
lobes and posterior cingulate gyrus are frequently affected
in (younger) AD patients and our visual rating scale was
designed to include these regions [3, 19, 21–26].
Visual rating of atrophy has shown to be a quick and
reproducible method to assess the degree of atrophy in a
clinical setting, compared to more labour intensive techniques
like volumetric analysis. For applicability in different clinical
settings or by different raters, good inter- and intra-rater
agreement is essential. Visual rating of MTA using a 5-point
scale has become fairly established and has shown fair to good
inter-rater agreement [9, 12, 37]. Visual rating of GCA seems
harder to perform reliably between different raters, while
despite moderate to good intra-rater agreement, poor inter-
rater agreement has been reported [35]. Our PA rating scale
varied between good and excellent inter- and intra-rater
agreement even between raters with different degrees of
expertise, suggesting its usefulness in a clinical setting as an
aid in assessment of PA. However, degree of agreement was
lower for PA compared to MTA (Table 2), which could be
due to the fact that visual assessment of MTA is applied for
many years in our memory clinic and raters gained much
experience. Visual assessment of PA on the contrary has not
been done before and our study is the first to assess the
applicability of visual assessment of PA in a clinical setting.
MTA is one of the most important markers of AD on MR
imaging. In the newly developed AD research criteria,
presence of early episodic memory decline and MTA is
sufficient for a diagnosis of prodromal AD [4]. MTA,
however, has been described in other dementias, which
makes MTA by itself less useful in the discrimination of
AD from other dementias [13–16, 18]. Furthermore, there is
an overlap in hippocampal volumes with normal aging,
Table 3 Linear regression analysis between visual rating scales (MTA
and PA) and MMSE and age
MTA PA
MMSE Model 1 −1.4 (0.5)* −1.7 (0.5)*
Model 2 −2.0 (0.5)* −1.8 (0.5)*
Model 3 −1.4 (0.5)* −1.6 (0.5)*
Age Model 1 3.1 (0.7)* 1.1 (0.8)
Model 2 3.1 (0.7)* 1.1 (0.8)
Model 3 3.1 (0.8)* 0.1 (0.8)
Results are presented as linear regression coefficients with standard
error, B (SE). Model 1 shows unadjusted associations, in model 2
there was a correction for sex and age in the analysis with the MMSE
and correction for sex in the analysis with age. In model 3 both visual
rating scales were entered simultaneously, together with the same
covariates
* p<0.01
MTA medial temporal lobe atrophy, PA posterior atrophy and MMSE
mini-mental state examination
Table 4 distribution of the presence of MTA and PA in AD patients
and controls
PA
absent present
AD patients MTA absent 16 (27%) 17 (28%)
MTA present 9 (15%) 18 (30%)
Controls MTA absent 33 (88%) 2 (5%)
MTA present 3 (8%) 0 (0%)
Other dementias MTA absent 9 (45%) 2 (10%)
MTA present 5 (25%) 4 (20%)
Data are presented as N (%). Scores on the visual rating scales were
dichotomized, an average score of >1 was considered abnormal for
both rating scales
AD Alzheimer’s disease, MTA medial temporal lobe atrophy, PA
posterior atrophy
Table 2 intra- and inter-rater agreement for MTA and PA visual rating
scales
MTA PA
Rater 1
Intra-rater Left 0.94 0.92
Agreement Right 0.94 0.92
Mean 0.95 0.93
Rater 2
Intra-rater Left 0.94 0.93
Agreement Right 0.91 0.93
Mean 0.94 0.95
Rater couple 1–2
Inter-rater Left 0.87 0.80
Agreement Right 0.90 0.84
Mean 0.90 0.84
Rater couple 1–3
Inter-rater Left 0.84 0.62
Agreement Right 0.82 0.67
Mean 0.86 0.65
Rater couple 2–3
Inter-rater Left 0.87 0.67
Agreement Right 0.85 0.70
Mean 0.90 0.70
Intra-rater agreement was determined in 29 examinations for 2 raters,
and inter-rater agreement was determined in 118 examinations for
three rater pairings. For weighted-kappa values the degree of
agreement was defined according to Landis and Koch [36] MTA
medial temporal lobe atrophy, PA posterior atrophy
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which could make the interpretation of MTA more difficult
in older subjects [17].
There is increasing evidence that posterior brain regions are
relatively more affected in EOAD and medial temporal lobe
structures may be less involved [19, 21–24, 26]. Several
clinico-pathological studies have reported involvement of the
posterior cingulate gyrus, parieto-occipital-, and temporopar-
ietal cortex in AD patients with typical as well as atypical
clinical presentations, although the combination with relative
sparing of the medial temporal lobe occurs especially in
patients presenting without prominent memory impairment
[3, 25, 28–30]. PA may be under-recognized, as clinicians
may be unaware of this relatively subtle MR imaging
characteristic of AD. Our visual assessment of PA was able
to discriminate AD from controls and other dementias,
whereas MTA failed to discriminate between AD and other
dementias. We found that a considerable proportion of AD
patients (28%) had prominent PA and mild or absent MTA,
whereas only 15% had prominent MTA and mild or absent
PA. Furthermore, combining MTA and PA increased the
sensitivity for AD. This underlines the importance of
evaluating PA in the diagnostic work-up of dementia.
Earlier studies showed that PA was more prominent in
younger AD patients [22, 26]. We found that the proportion
of patients with predominant PA was higher in EOAD
compared to late-onset AD (34% versus 20%). Further-
more, patients with only prominent PA were younger than
patients with only prominent MTA, although this difference
did not reach statistical significance. However, we did not
find a direct relation between PA and age with linear-
regression analysis.
A previous study has shown that MTA is correlated with
memory deficits and lower MMSE scores in AD [9]. PA
seems to have clinical relevance as well, since PA was
clearly associated with lower MMSE scores, independent of
MTA. This is perhaps not surprising, given the importance
of posterior (non-memory) aspects of the MMSE, such as
calculation and visuospatial function.
A limitation of our study is lack of pathological
confirmation of the diagnoses. We therefore cannot exclude
other underlying abnormalities or mixed disease processes.
However, all patients were carefully screened and fulfilled
clinical criteria for the specific dementia types. It should be
noted that our cohort consisted of relatively young AD
patients, which could have influenced our results, since PA
may be relatively more common in younger patients.
Before generalisation of our results to older AD patients,
further research is necessary to determine the prevalence of
PA in large numbers of young and elderly AD patients and
assess its discriminative power and the potential influence
of age on its utility.
A considerable number of patients attending a memory
clinic are not able to undergo MR imaging for any number
of reasons (e.g. pacemaker, limited availability ofMR imaging
etc.) and computed tomography (CT) could be an alternative.
Visual assessment of MTA has found to be comparable on CT
and MR imaging and future work should address whether our
rating scale is also applicable for CT [38].
In conclusion this study provides an easy applicable and
robust visual rating scale to assess PA. Measurement of PA
using this visual rating scale appears to add value in the
discrimination of AD from controls and other dementias
(FTLD and DLB) on MRI.
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